FDA 483 - Polpharma Biologics S.A

The FDA inspection of Polpharma Biologics S.A. in Gdańsk, Poland, revealed multiple significant deficiencies in their drug substance manufacturing processes. Key issues include inadequate process validation, insufficient cleaning and disinfection controls, and a lack of proper documentation for changes and investigations. These observations indicate a need for comprehensive improvements in quality systems and operational procedures.